The development of new therapies is an arduous, time-consuming and costly task. Furthermore, the development of many compounds runs into issues related to safety. Drug repurposing, where drugs with established safety in humans are tested and developed for efficacy in a disease other than the one for which they were developed, is gaining traction because of its potential to overcome an initial bottleneck in the drug development process. In “Bedside to Bench,” Stephen Strittmatter discusses the types of scenario in which drug repurposing may be of benefit, such as when a drug is repurposed for a new molecular target or for the same target in a different disease. In “Bench to Bedside,” Michael Pollak focuses on a recent study that suggest that biguanides that are normally used in the treatment of diabetes could have direct cyotoxic action on cancer cells with mutations in respiratory complex I. The pharmacokinetic hurdles that may need to be overcome for this to be translated to the clinic are also discussed.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Drug–target affinity prediction with extended graph learning-convolutional networks
BMC Bioinformatics Open Access 16 February 2024
-
Making sense of chemical space network shows signs of criticality
Scientific Reports Open Access 04 December 2023
-
DGDTA: dynamic graph attention network for predicting drug–target binding affinity
BMC Bioinformatics Open Access 30 September 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Scannell, J.W., Blanckley, A., Boldon, H. & Warrington, B. Nat. Rev. Drug Discov. 11, 191–200 (2012).
DiMasi, J.A., Feldman, L., Seckler, A. & Wilson, A. Clin. Pharmacol. Ther. 87, 272–277 (2010).
Arrowsmith, J. & Miller, P. Nat. Rev. Drug Discov. 12, 569 (2013).
Nygaard, H.B., van Dyck, C.H. & Strittmatter, S.M. Alzheimers Res. Ther. 6, 8 (2014).
Rothstein, J.D. et al. Nature 433, 73–77 (2005).
Berry, J.D. et al. PLoS ONE 8, e61177 (2013).
Zhou, Y. et al. Science 302, 1215–1217 (2003).
Wang, X. et al. J. Neurotrauma 26, 81–95 (2009).
Kopp, M.A. et al. Cell Tissue Res. 349, 119–132 (2012).
Lin, T.S. & Prusoff, W.H. J. Med. Chem. 21, 109–112 (1978).
Yarchoan, R. & Broder, S. N. Engl. J. Med. 316, 557–564 (1987).
Nair, P. Proc. Natl. Acad. Sci. USA 110, 2430–2432 (2013).
Hennequin, L.F. et al. J. Med. Chem. 49, 6465–6488 (2006).
Kulkarni, J. et al. Schizophr. Res. 48, 137–144 (2001).
Hilbish, K.G., Breslin, W.J., Johnson, J.T. & Sloter, E.D. Birth Defects Res. B Dev. Reprod. Toxicol. 98, 400–415 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Strittmatter, S. Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks. Nat Med 20, 590–591 (2014). https://doi.org/10.1038/nm.3595
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3595
This article is cited by
-
Drug–target affinity prediction with extended graph learning-convolutional networks
BMC Bioinformatics (2024)
-
DGDTA: dynamic graph attention network for predicting drug–target binding affinity
BMC Bioinformatics (2023)
-
Making sense of chemical space network shows signs of criticality
Scientific Reports (2023)
-
Discovery of Small Molecule PARKIN Activator from Antipsychotic/Anti-neuropsychiatric Drugs as Therapeutics for PD: an In Silico Repurposing Approach
Applied Biochemistry and Biotechnology (2023)
-
Oxethazaine inhibits esophageal squamous cell carcinoma proliferation and metastasis by targeting aurora kinase A
Cell Death & Disease (2022)